Compare FRME & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRME | EVO |
|---|---|---|
| Founded | 1893 | 1993 |
| Country | United States | Germany |
| Employees | 2086 | 4553 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | FRME | EVO |
|---|---|---|
| Price | $40.27 | $3.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $48.33 | $7.00 |
| AVG Volume (30 Days) | ★ 260.3K | 47.1K |
| Earning Date | 04-22-2026 | 04-08-2026 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $27.67 | $1.37 |
| Revenue Next Year | $5.91 | $10.05 |
| P/E Ratio | $10.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $34.66 | $2.31 |
| 52 Week High | $43.22 | $4.42 |
| Indicator | FRME | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 52.73 | 56.03 |
| Support Level | $38.74 | $2.88 |
| Resistance Level | $41.82 | $3.75 |
| Average True Range (ATR) | 0.79 | 0.07 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 66.05 | 89.58 |
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment, which is community banking.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.